The topical hormonal acne treatment covered in a 2026 review is clascoterone 1% cream, sold as Winlevi. It is a topical androgen-receptor inhibitor, meaning a prescription cream that blocks male-hormone signals in the skin.
According to Drugs.com, it was FDA-approved Aug. 26, 2020 for acne vulgaris in patients age 12 and older as the first drug of this type the FDA approval history. For readers, that means one prescription option targets oil and inflammation at the hormone receptor inside pores and hair follicles.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does it target hormonal breakouts?
- How do you use the cream?
- What did trials show?
- Where does it fit in 2026 care?
How does it target hormonal breakouts?
Skin Therapy Letter explains that clascoterone competes with natural androgens at receptors in sebaceous glands and hair follicles. By blocking dihydrotestosterone signaling, it reduces sebum production and proinflammatory signals. Less oil and less inflammation mean fewer clogged pores and red bumps.
This local action is the key difference from birth control pills or spironolactone. Those treatments act through the whole body. This cream acts where it is applied.
How do you use the cream?
The labeled routine is simple and steady. Western Health Advantage, citing the prescribing information, describes a thin uniform layer to affected skin twice daily, morning and evening, for topical use only the provider monograph.
Safety under age 12 is unestablished. The product is prescription-only, so a clinician must weigh fit, skin sensitivity, and other topicals.
- Apply a thin, even layer to acne-prone areas morning and evening
- Use on skin only, exactly as prescribed
- Keep using it over time rather than stopping after a few weeks
What did trials show?
Two identical 12-week phase 3 trials with about 1,440 participants total found clascoterone superior to vehicle. The Clinical, Cosmetic and Investigational Dermatology review reports better treatment success and greater inflammatory and noninflammatory lesion reductions the 2025 narrative review. Benefit grew with continued use in longer follow-up.
Healio Dermatology reported in Jan. 2024 that efficacy increased with persistent use up to 12 months. That pattern supports continuous treatment rather than a short course for many teens and adults.
Where does it fit in 2026 care?
The American Academy of Dermatology 2024 acne guidelines conditionally recommend clascoterone with high certainty of benefit, while stronger recommendations remain for benzoyl peroxide, retinoids, and fixed combinations, as reported by MDedge and The Hospitalist the AAD guideline report. Practical Dermatology notes in-vitro support for pairing it with a retinoid, benzoyl peroxide, or antibiotic approach.
Cost and irritation shape real-world choice. Managed Healthcare Executive noted AAD concern that high price may limit equitable access, and labeling notes local irritation plus reversible adrenal-gland signal changes in testing. Ask your dermatologist about a two- or three-product topical plan, irritation control, and pharmacy cost before starting.
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Why the Findings May Not Change Acne Care Yet for Teens With Inflammatory Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: Who Was Studied and Who Was Not for Teens With Inflammatory Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: Who Was Studied and Who Was Not for Teens With Inflammatory Acne